| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Lauric acid-d23 itself does not have a traditional biological target; it is a stable isotope-labeled internal standard. The parent compound lauric acid is a medium-chain saturated fatty acid with strong antibacterial effects, with EC50 values of 2, 6, and 4 μg/mL against Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis, respectively. Lauric acid-d23 is used to track and quantify lauric acid in biological samples for metabolic studies.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Lauric acid-d23 itself does not exhibit direct in vitro biological activity as it is an analytical standard. However, the parent compound lauric acid is a medium-chain saturated fatty acid with strong antibacterial effects against various bacterial strains, including Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis with EC50 values of 2, 6, and 4 μg/mL, respectively. Lauric acid-d23 is used as an internal standard to accurately measure lauric acid concentrations in antibacterial assays and other biological samples. |
| ln Vivo |
Lauric acid-d23 is not intended for in vivo administration as a therapeutic agent; it is used as an analytical standard. The in vivo activity of the parent compound lauric acid is associated with its antibacterial and metabolic effects. Lauric acid-d23 is utilized in pharmacokinetic and metabolic studies to track the distribution, metabolism, and excretion of lauric acid in animal models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for lauric acid-d23 are not typically performed, as it is an analytical standard. Instead, the compound is used in analytical method development and validation. Quality control assays involve HPLC or LC-MS/MS to verify isotopic purity (≥98 atom % D) and chemical purity (≥98%). The compound is tested for stability under various storage conditions. It appears as a white solid with a melting point of 39-41°C.
|
| Cell Assay |
Lauric acid-d23 itself is not tested in in vitro cellular assays for biological activity, as it is an analytical standard. Its utility is assessed by its performance as an internal standard in analytical workflows, including its ability to co-elute with the parent compound and provide accurate quantification in LC-MS/MS or GC-MS analyses. The compound is used in quality control applications for fatty acid analysis.
|
| Animal Protocol |
In vivo animal studies for lauric acid-d23 are not conducted as therapeutic efficacy studies. Instead, the compound is administered to animals as a tracer in pharmacokinetic and metabolic studies to quantify the parent compound lauric acid in plasma, tissues, and excreta. These studies help determine the absorption, distribution, metabolism, and excretion (ADME) profile of lauric acid. The labeled compound allows for precise tracking and identification of the fatty acid in biological matrices.
|
| ADME/Pharmacokinetics |
Lauric acid-d23 has a molecular formula of C₁₂HD₂₃O₂ and a molecular weight of 223.46. The compound appears as a white solid with a purity of ≥98% and an isotopic enrichment of ≥98 atom % D. It has a melting point of 39-41°C and is slightly soluble in DMSO and methanol. The compound is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of lauric acid-d23 is not extensively characterized, as it is an analytical standard rather than a therapeutic agent. The parent compound lauric acid is a medium-chain fatty acid that is generally recognized as safe in moderate amounts. Lauric acid-d23 is intended for research use only and is not approved for clinical use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Lauric acid-d23 (CAS 59154-43-7) is a perdeuterated stable isotope-labeled analog of the 12-carbon medium-chain saturated fatty acid, lauric acid. It has a molecular formula of C₁₂HD₂₃O₂ and a molecular weight of 223.46. It is intended for use as an internal standard for the quantification of lauric acid by GC- or LC-MS. Lauric acid has strong antibacterial effects. Lauric acid-d23 is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
C12HD23O2
|
|---|---|
| Molecular Weight |
223.46
|
| Exact Mass |
223.321
|
| CAS # |
59154-43-7
|
| Related CAS # |
Lauric acid;143-07-7;Lauric acid-d2;64118-39-4
|
| PubChem CID |
16212944
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
296.1±3.0 °C at 760 mmHg
|
| Melting Point |
44-46ºC(lit.)
|
| Flash Point |
134.1±11.9 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.448
|
| LogP |
5.03
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
14
|
| Complexity |
132
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C(=O)O
|
| InChi Key |
POULHZVOKOAJMA-SJTGVFOPSA-N
|
| InChi Code |
InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)/i1D3,2D2,3D2,4D2,5D2,6D2,7D2,8D2,9D2,10D2,11D2
|
| Chemical Name |
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,12-tricosadeuteriododecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (447.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4751 mL | 22.3754 mL | 44.7507 mL | |
| 5 mM | 0.8950 mL | 4.4751 mL | 8.9501 mL | |
| 10 mM | 0.4475 mL | 2.2375 mL | 4.4751 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
